Market Place
Sourcing Support
Arcutis’ ZORYVE® Awarded Best Eczema Treatment by Glamour
13 Nov 2024 //
GLOBENEWSWIRE
Arcutis Drug Recieves Canada Approval to Treat Seborrheic Dermatitis
19 Oct 2024 //
GLOBENEWSWIRE
FDA Accepts Arcutis’ Application for ZORYVE Foam for Scalp Psoriasis
24 Sep 2024 //
GLOBENEWSWIRE
Zoryve Cream 0.15% Shows Improvement in Atopic Dermatitis Patients
24 Sep 2024 //
GLOBENEWSWIRE
Arcutis Announces Positive Results For Roflumilast Cream In Children
28 Aug 2024 //
GLOBENEWSWIRE
Arcutis Launches ZORYVE® Cream For Atopic Dermatitis Treatment
29 Jul 2024 //
GLOBENEWSWIRE
Arcutis Announces ZORYVE® Co-Promote Agreement With Kowa Pharma
29 Jul 2024 //
GLOBENEWSWIRE
Arcutis Submits sNDA For ZORYVE Foam For Scalp And Body Psoriasis
23 Jul 2024 //
GLOBENEWSWIRE
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
22 Jul 2024 //
GLOBENEWSWIRE
FDA Approves Atopic Dermatitis Label Expansion for Arcutis’ Zoryve Cream
11 Jul 2024 //
PRESS RELEASE
Arcutis Updates On Roflumilast Cream SNDA For Atopic Dermatitis
09 Jul 2024 //
GLOBENEWSWIRE
FDA Approves Arcutis ZORYVE Cream For Atopic Dermatitis Treatment
09 Jul 2024 //
GLOBENEWSWIRE
Expert Panel Validates ZORYVE Topical Foam For Seborrheic Dermatitis Across Hair
13 May 2024 //
GLOBENEWSWIRE
Arcutis Presents Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast
10 Mar 2024 //
GLOBENEWSWIRE
Arcutis and Sato Announce Strategic Collaboration
28 Feb 2024 //
GLOBENEWSWIRE
Journal of the American Academy of Dermatology Publishes ZORYVE Results
29 Jan 2024 //
GLOBENEWSWIRE
ZORYVE for the Treatment of Seborrheic Dermatitis Launches in USA
22 Jan 2024 //
GLOBENEWSWIRE
Arcutis` Zoryve has snagged a 2nd dermatology nod from FDA
16 Dec 2023 //
FIERCE PHARMA
FDA Accepts Arcutis™ Supplemental New Drug Application for Roflumilast Cream
29 Nov 2023 //
GLOBENEWSWIRE
New Data Shows ZORYVE Provided Measurable Improvement of Plaque Psoriasis
20 Oct 2023 //
GLOBENEWSWIRE
Arcutis Announces Positive Results from Phase 3 Trial of Roflumilast
19 Sep 2023 //
GLOBENEWSWIRE
Arcutis Submits Roflumilast Cream Supplemental New Drug Application to the FDA
12 Sep 2023 //
GLOBENEWSWIRE
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15%
07 Sep 2023 //
GLOBENEWSWIRE
Arcutis and Huadong Announce Collaboration for Topical Roflumilast
10 Aug 2023 //
GLOBENEWSWIRE
Arcutis Announces ZORYVE Has Been Included in a Preferred Position on National Formularies for CVS Caremark
17 Jul 2023 //
GLOBENEWSWIRE
Arcutis Announces Q1 2023 Financial Results and Provides Business Update
09 May 2023 //
PRESS RELEASE
Arcutis Completes Enrollment in INTEGUMENT-PED Phe3 Trial Roflumilast Cream
02 May 2023 //
GLOBENEWSWIRE
Arcutis Announces Approval of Zoryve Cream for Treatment of Plaque Psoriasis
29 Apr 2023 //
PRESS RELEASE
Zydus gets final USFDA approval to manufacture generic anti-inflammation drug
20 Apr 2023 //
TRIBUNEINDIA
Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast
18 Apr 2023 //
GLOBENEWSWIRE
Arcutis Announces New Coverage for ZORYVE Cream 0.3%
05 Apr 2023 //
GLOBENEWSWIRE
Arcutis to Present Roflumilast Data Including Atopic Dermatitis Trial Data
09 Mar 2023 //
GLOBENEWSWIRE
Arcutis Biotherapeutics reports data from roflumilast cream trial
16 Jan 2023 //
CLINICAL TRIALS ARENA
Arcutis Submits Supplemental New Drug Application for ZORYVE Cream
19 Dec 2022 //
GLOBENEWSWIRE
Arcutis Announces Results from Pivotal Phase 3 Trial of Roflumilast
13 Dec 2022 //
BIOSPACE
Arcutis Announces +ve Results from Atopic Dermatitis Ph3 Trial of Roflumilast
12 Dec 2022 //
GLOBENEWSWIRE
Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.
17 Nov 2022 //
GLOBENEWSWIRE
Arcutis Announces Positive Results from Phase 3 Trial of Roflumilast
15 Nov 2022 //
GLOBENEWSWIRE
Arcutis Announces Positive Results from Phase 3 Trial of Roflumilast
15 Nov 2022 //
GLOBENEWSWIRE
Arcutis Announces Positive Results from PIII Trial of Roflumilast
27 Sep 2022 //
GLOBENEWSWIRE
Journal of the American Medical Association Publishes Roflumilast Cream
20 Sep 2022 //
GLOBENEWSWIRE
New Data from Arcutis’ STRATUM PIII Trial of Roflumilast
09 Sep 2022 //
GLOBENEWSWIRE
MSN`s Generic Roflumilast Receives Approval in the U.S.
07 Sep 2022 //
FDA
Arcutis will soon file roflumilast foam for new potential nod
06 Sep 2022 //
FIERCEPHARMA
Arcutis Announces Arcutis Cares PAP
22 Aug 2022 //
GLOBENEWSWIRE
Armed with $570M war chest, Arcutis launches psoriasis cream
15 Aug 2022 //
FIERCEPHARMA
Arcutis to Host Investor Conference Call to Discuss the FDA Approval of ZORYVE
01 Aug 2022 //
GLOBENEWSWIRE
Arcutis pulls in a win for its topical version of an old AZ drug
30 Jul 2022 //
ENDPTS
Health Canada accepts Arcutis Bio`s NDA Review for Roflumilast Cream
11 Jul 2022 //
GLOBENEWSWIRE
Arcutis Shows Positive Results from STRATUM PIII Trial of Roflumilast Foam 0.3%
06 Jun 2022 //
GLOBENEWSWIRE
Prinston Pharma Generic Roflumilast Receives Approval in U.S
10 May 2022 //
FDA
Arcutis Completes Enrollment in Phase 3 Trial of Topical Roflumilast Foam
06 Apr 2022 //
GLOBENEWSWIRE
Arcutis` Roflumilast Foam Shows Results in Phase 2 Seborrheic Dermatitis Study
25 Mar 2022 //
GLOBENEWSWIRE
Zydus Pharmaceuticals (USA) gets final FDA approval to market Roflumilast
14 Feb 2022 //
ECONOMIC TIMES
Zydus Pharms` Generic Roflumilast Receives Approval in the U.S.
10 Feb 2022 //
FDA
Even as topical, shaking JAK concerns may be tough for Opzelura
12 Nov 2021 //
FIERCEPHARMA
Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA
04 Oct 2021 //
GLOBENEWSWIRE
